Yahoo Finance report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Why IOSP Stock slipped -1.50% Today — RQD Quant Desk Flash
Innospec Inc. (IOSP) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (28% profit margin, 10% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IOSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Innospec Inc. (NASDAQ: IOSP) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $99.89 (-1.50% 1D, market cap $2.50B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 13/20. Across 270 tracked Materials issuers, IOSP ranks #10 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IOSP compare to ROG and NGVT in the Materials sector?
▼
Within the Materials sector (Major Chemicals), IOSP carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of 27.7%, and ROIC of 9.9%. By comparison, ROG (Rogers Corporation) holds a D grade (51/100 RQD, P/E N/A, ROIC -3.6%, cap $2.50B) and NGVT (Ingevity Corporation) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 85.0%, cap $2.59B). Among the 5-stock peer group, WDFC leads on earnings multiple (32.3x) while NGVT leads on capital efficiency (85.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IOSP?
▼
Per IOSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054905), Innospec Inc. generated $1.78B in revenue (-3.7% YoY), $0 in net income, and $138.3M in free cash flow against $1.83B in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±4% realized swing band)
SEC XBRL FY 2025 (10-K): 7.8% FCF Margin ($138.3M FCF) & 27.7% Gross Margin
Cannibal Buyback (-1.52% YoY Shares) & executive Form 4 sales trim 7 pts from alignment
⚔️ Adversarial Opposing Case: Why the IOSP Bull Thesis Could Fail
Even with a 70/100 (B-) score, IOSP faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 25.2% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($96.19) or 200D SMA ($84.47) invalidates the momentum regime and cuts Target Base ($105.28) toward Bear Floor ($81.91).
Why IOSP Stock slipped -1.50% Today — RQD Quant Desk Flash
Innospec Inc. (IOSP) slipped -1.50% to $99.89, trading at 94% of its 52-week range ($65.51 – $102). High-quality cash engine (28% profit margin, 10% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 94% of its 52-week range ($65.51 – $102) with RSI-14 at 64.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4% around $99.89 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 27.7% gross margin and $138.3M annual free cash flow.
TradingView report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Olin (OLN) delivered earnings and revenue surprises of +40.00% and -2.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Albemarle (ALB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is how Avient (AVNT) and Innospec (IOSP) have performed compared to their sector so far this year.
Scheduled RQD Strong Buys & Whale Accumulation Briefing (IOSP Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
IOSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IOSP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IOSP. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IOSP)
1. Head-to-Head Materials Peer Comparison (IOSP vs. ROG, NGVT, KWR, WDFC)
Industry: Major Chemicals (67 Tracked Issuers)Across 270 tracked Materials securities in the Roarable RQD universe, Innospec Inc. (IOSP) ranks #10 by composite RQD confidence (70/100, grade B-) and #103 by equity capitalization ($2.50B). Within this direct 5-issuer industry benchmark cohort, WDFC leads on earnings valuation at 32.3x trailing P/E, while NGVT leads on capital efficiency and profitability with 85.0% ROIC and 39.5% gross margin. IOSP currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IOSP
ACTIVE
Innospec Inc. | B- | 70/100 | — | 27.7% | 9.9% | -1.50% | $2.50B | Benchmark Subject |
| ROG Rogers Corporation | D | 51/100 | — | 31.7% | -3.6% | -5.18% | $2.50B | /rog-vs-iosp → |
| NGVT Ingevity Corporation | C+ | 67/100 | — | 39.5% | 85.0% | -1.39% | $2.59B | /ngvt-vs-iosp → |
| KWR Quaker Houghton | D | 49/100 | — | 36.0% | 2.1% | -4.38% | $2.72B | /kwr-vs-iosp → |
| WDFC WD-40 Company | C+ | 69/100 | 32.3x | 55.1% | 27.2% | +0.55% | $2.94B | /wdfc-vs-iosp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001054905In its most recent audited fiscal period (FY2025, filed 2025-12-31), Innospec Inc. (IOSP) reported GAAP revenue of $1.78B (-3.7% vs. FY2024 revenue of $1.85B , and -8.8% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $138.3M, and free cash flow of $138.3M (-25.0% YoY). On the balance sheet, IOSP closed FY2025 with $1.83B in total assets against $0 in total debt (Altman Z-Score: 5.47, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.78B | $0 | $138.3M | $138.3M | $1.83B | — |
| FY2024 (FY) | 2024-12-31 | $1.85B | $0 | $184.5M | $184.5M | $1.73B | — |
| FY2023 (FY) | 2023-12-31 | $1.95B | $0 | $207.3M | $207.3M | — | — |
3. IOSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IOSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Innospec Inc. (NASDAQ: IOSP) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $99.89 (-1.50% 1D, market cap $2.50B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 13/20. Across 270 tracked Materials issuers, IOSP ranks #10 in composite RQD confidence.
How does IOSP compare to ROG and NGVT in the Materials sector?
Within the Materials sector (Major Chemicals), IOSP carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of 27.7%, and ROIC of 9.9%. By comparison, ROG (Rogers Corporation) holds a D grade (51/100 RQD, P/E N/A, ROIC -3.6%, cap $2.50B) and NGVT (Ingevity Corporation) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 85.0%, cap $2.59B). Among the 5-stock peer group, WDFC leads on earnings multiple (32.3x) while NGVT leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IOSP?
Per IOSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054905), Innospec Inc. generated $1.78B in revenue (-3.7% YoY), $0 in net income, and $138.3M in free cash flow against $1.83B in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IOSP trading relative to its 50-day, 200-day, and 52-week technical levels?
IOSP last traded at $99.89 (-1.50% on volume of 216,494 shares), positioning the stock +3.85% above its 50-day simple moving average ($96.19) and +18.26% above its 200-day simple moving average ($84.47). Across its 52-week range of $65.51 to $102.00, IOSP sits at the 94.2% percentile with a 14-day RSI of 64.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.0% ($95.89 to $103.89).
IOSP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IOSP stock moving today?
Why IOSP Stock slipped -1.50% Today — RQD Quant Desk Flash. High-quality cash engine (28% profit margin, 10% return on capital) with steady institutional support.
IOSP — Innospec Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IOSP scores 70 out of 100 with a letter grade of B- and a verdict of "Roarable Buy — Sound Institutional Accumulation." The five pillars are: Fundamental Cash Engine at 14/20 (ROIC 9.9%; FCF yield 5.54%), Whale 13F Flow at 16/20 (institutional accumulation and options positioning), Insider Conviction at 13/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 13/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet at 14/20 (Altman Z 5.47; Piotroski F 4/9; Debt/Equity 0.5). The strongest pillar is institutional flow, while insider conviction and macro fit sit lower. For a prospective investor, the upside case rests on the cash-generation and balance-sheet pillars combined with accumulation signals. The valuation tradeoff is that the shares trade at an EV/EBITDA of 17 with a 5.54% FCF yield, and the source data does not provide P/E or EPS to frame earnings-based valuation. The rating is a source-derived scoring output, not a recommendation to act.
Business
Innospec Inc. is a NASDAQ-listed issuer in the Materials sector, operating within the Major Chemicals industry, per the Profile section. The source data does not describe its products, customers, or revenue model beyond the sector classification. The Snapshot and Financial Trend sections show reported revenue of $1778.0M for FY 2025, but the source data does not explain how the company earns that revenue.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1778.0M | $129.5M | $0.0M | N/A | $138.3M | $292.5M | N/A |
| FY 2024 | $1845.4M | $177.9M | $0.0M | N/A | $184.5M | $289.2M | N/A |
| FY 2023 | $1948.8M | $161.6M | $0.0M | N/A | $207.3M | N/A | N/A |
Per the SEC financials, revenue declined across the three reported periods, and operating income fell from $177.9M in FY 2024 to $129.5M in FY 2025. Reported net income is $0.0M in each period and EPS is N/A. Per the market data, gross margin is 27.7%, operating margin 7.3%, and net margin 0%. ROIC is 9.9%. Per the RQD forensic pillar, Altman Z is 5.47, Piotroski F is 4/9, and Debt/Equity is 0.5. Cash was $292.5M in FY 2025, and the source data does not provide debt figures.
Recent Catalysts & News Wire Analysis
The news wire lists six items, all tagged to IOSP, from Yahoo Finance, TradingView, Simply Wall St, Benzinga, and Stock Traders Daily. Headlines reference stock forecasts, estimates ahead of an upcoming earnings release, a report that the stock could be 25% undervalued despite steady cash flow, a Q2 2026 earnings call transcript, and rotational strategy timing. Each item carries a YELLOW light and a MARKET WIRE impact label. The summaries are generic and do not contain specific figures. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Risk watch items are not specified in the source data beyond the general statement that the earnings release is upcoming.
Open Questions
- What are IOSP's reported debt and EPS figures, which the financials leave as N/A or unreported, and how do they affect the forensic and valuation assessment?
- What drove the decline in revenue and operating income across FY 2023 through FY 2025?
- What is the basis for the 25% undervaluation claim referenced in the news wire, and what cash flow assumptions does it rely on?
- What are the company's products, customers, and principal sources of revenue?
- What do the upcoming earnings expectations specifically imply for the next reporting period?
IOSP Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Innospec Inc. (IOSP) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Innospec Inc. (IOSP) market action, institutional positioning, and fundamental catalysts.
Olin (OLN) delivered earnings and revenue surprises of +40.00% and -2.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
IOSP Bull vs. Bear Conversation Board — What's Your Call at $99.89?
🔥 Official Bull vs. Bear Debate: Is IOSP (B- • RQD 70/100) a Buy at $101.41?
Welcome to the IOSP (Innospec Inc.) Roar Pit. Current RQD Composite is 70/100 (Roarable Buy — Sound Institutional Accumulation) in Major Chemicals. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on IOSP — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IOSP, but look at what you are paying: current EV/EBITDA multiples with 27.7% gross margins. Unless Innospec Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
IOSP cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IOSP, the market is fixating on short-term headline noise in Major Chemicals and ignoring the balance sheet and cash flow trajectory. At $101.41 (52-wk range $65.51 - $102.00), any beat on forward guidance forces shorts and underweight funds to chase.